Could immunotherapy let surgeons do less without hurting survival?
NCT ID NCT07320690
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether people with advanced head and neck cancer who respond to immunotherapy can safely have a smaller, less invasive surgery than usual. The goal is to preserve organ function and quality of life without lowering the chance of survival. About 356 participants will be randomly assigned to either standard surgery or a reduced surgery based on post-immunotherapy tumor boundaries.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
immunotherapy (neoadjuvant) followed by de-escalation surgery
What this could lead to
If successful, this approach could allow many patients to have smaller, less disfiguring surgeries while still controlling their cancer.
What could go wrong
This is a Phase 3 trial, but it is not yet recruiting. The non-inferiority design means it aims to show that less surgery is not worse than standard surgery, but there is a risk that survival could be slightly worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Ninth Peolple's Hospital
Shanghai, Shanghai Municipality, 200000, China